Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remternetug - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Remternetug - Eli Lilly and Company

Alternative Names: LY-3372993; N3pG 4; N3PG-IV

Latest Information Update: 06 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Pyroglutamyl(3)-amyloid beta-protein (3-42) inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 22 Nov 2024 Phase-II/III clinical trials in Alzheimer's disease (Early-stage disease) in United Kingdom, Spain, Puerto Rico, Netherlands, Mexico, Italy, Ireland, Germany, France, Colombia, Canada, Australia, Argentina (SC) (NCT06647498)
  • 22 Nov 2024 Eli Lilly and Company in collaboration with Washington University School of Medicine initiates a phase II/III in Alzheimer's in the USA (SC) (NCT06647498)
  • 22 Nov 2024 Eli Lilly and Company in collaboration with Washington University School of Medicine initiates a phase II/III in Alzheimer's in the USA (SC) (NCT05552157)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top